Skip to main content
    U

    Ultragenyx (RARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.90
    -0.18 (-1.12%)

    Market Cap: $1.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ultragenyx (RARE) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Ultragenyx (RARE) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Ultragenyx reported EPS of -$1.16, below the -$1.15 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    33%(13/40)
    Avg Surprise
    -12.89%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.51
    Range-$1.18 - $3.11
    22 analysts
    Revenue Consensus
    $228.28M
    Range$187.18M - $249.66M
    20 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.04
    Range-$0.45 - $0.63
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.27-114.8%
    60d ago-$0.47+91.5%
    30d ago-$0.44+90.9%
    7d ago-$0.44+90.9%
    Current-$0.04
    Revenue Consensus
    $198.70M
    Range$159.00M - $312.10M
    9 analysts

    Next Report

    RARE has an expected report date of Feb 10, 2027.

    RARE Earnings Call

    The latest RARE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, RARE beat 13, missed 26 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $173.00M, up 8.1% from $160.00M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.16-$1.15-$1.25 - $0.75-0.87%MissN/A60 up, 1 downNov 3, 2026$173.00M
    Jun 30, 2026-$0.90-$1.27N/A+29.13%BeatN/A20 up, 3 downAug 4, 2026$214.00M
    Mar 31, 2026-$1.54-$1.46-$2.01 - -$0.78-5.48%MissN/A110 up, 2 downMay 5, 2026$136.00M
    Dec 31, 2025-$1.29-$1.17-$1.76 - -$0.71-10.26%MissN/A122 up, 1 downFeb 12, 2026$207.28M
    Sep 30, 2025-$1.81-$1.21-$1.39 - -$0.98-49.59%MissN/A12N/ANov 4, 2025$160.00M
    Jun 30, 2025-$1.17-$1.32-$1.41 - -$1.11+11.36%BeatN/A117 up, 1 downAug 5, 2025$167.00M
    Mar 31, 2025-$1.57-$1.64-$2.41 - -$1.18+4.27%BeatN/A100 up, 1 downMay 6, 2025$139.00M
    Dec 31, 2024-$1.39-$1.27-$1.48 - -$1.01-9.45%MissN/A112 up, 0 downFeb 13, 2025$164.65M
    Sep 30, 2024-$1.40-$1.47-$1.76 - -$0.88+4.76%BeatN/A181 up, 0 downNov 5, 2024$139.49M
    Jun 30, 2024-$1.52-$1.63-$2.13 - -$1.41+6.75%BeatN/A172 up, 0 downAug 1, 2024$147.03M
    Mar 31, 2024-$2.03-$1.72-$2.04 - -$1.39-18.02%MissN/A181 up, 0 downMay 2, 2024$108.83M
    Dec 31, 2023-$1.52-$1.61-$2.45 - -$0.71+5.59%BeatN/A161 up, 0 downFeb 15, 2024$127.14M
    Sep 30, 2023-$2.23-$2.01-$2.71 - -$1.55-10.95%MissN/A151 up, 4 downNov 2, 2023$98.05M
    Jun 30, 2023-$2.25-$2.02-$2.32 - -$1.63-11.39%MissN/A171 up, 0 downAug 3, 2023$108.31M
    Mar 31, 2023-$2.33-$1.61-$2.91 - -$1.55-44.72%MissN/A171 up, 0 downMay 4, 2023$100.50M
    Dec 31, 2022-$2.19-$1.80-$3.33 - -$1.60-21.67%MissN/A173 up, 0 downFeb 16, 2023$103.35M
    Sep 30, 2022-$3.48-$2.40-$3.04 - $4.63-45.00%MissN/A161 up, 1 downNov 2, 2022$90.70M
    Jun 30, 2022-$2.12-$1.64-$2.31 - -$1.22-29.27%MissN/A161 up, 0 downJul 28, 2022$89.34M
    Mar 31, 2022-$2.06-$1.78-$2.21 - -$1.45-15.73%MissN/A161 up, 0 downMay 5, 2022$79.94M
    Dec 31, 2021-$1.55-$1.19-$1.73 - -$0.77-30.25%MissN/A173 up, 1 downFeb 10, 2022$83.39M
    Sep 30, 2021-$1.45-$1.10-$1.83 - -$0.93-31.82%MissN/A18N/ANov 2, 2021$81.65M
    Jun 30, 2021-$1.35-$1.05-$2.27 - -$0.97-28.57%MissN/A16N/AAug 2, 2021$86.97M
    Mar 31, 2021-$1.72-$1.29-$1.81 - -$0.77-33.33%MissN/A14N/AMay 4, 2021$99.39M
    Dec 31, 2020-$1.59-$1.14-$1.91 - -$0.69-39.47%MissN/A16N/AFeb 11, 2021$91.54M
    Sep 30, 2020-$0.94-$1.06-$1.75 - -$0.53+11.32%BeatN/A15N/AOct 27, 2020$81.47M
    Jun 30, 2020-$1.14-$1.72-$1.79 - -$0.82+33.72%BeatN/A16N/AJul 30, 2020$61.71M
    Mar 31, 2020-$2.04-$1.68-$2.45 - -$1.38-21.43%MissN/A16N/AMay 6, 2020$36.31M
    Dec 31, 2019-$1.62-$1.53-$1.98 - -$1.46-5.88%MissN/A16N/AFeb 13, 2020$35.59M
    Sep 30, 2019-$2.00-$1.55-$1.97 - -$1.49-29.03%MissN/A16N/ANov 5, 2019$25.80M
    Jun 30, 2019-$1.90-$1.59-$1.81 - -$1.45-19.50%MissN/A16N/AAug 1, 2019$24.15M
    Mar 31, 2019-$1.82-$1.67-$1.90 - -$1.53-8.98%MissN/A16N/AMay 6, 2019$18.17M
    Dec 31, 2018-$1.73-$1.79-$2.28 - -$1.26+3.35%BeatN/A16N/AFeb 19, 2019$16.26M
    Sep 30, 2018-$1.74-$1.99-$2.15 - -$1.81+12.56%BeatN/A17N/ANov 5, 2018$11.76M
    Jun 30, 2018-$1.87-$2.13-$2.20 - -$1.92+12.21%BeatN/A17N/AAug 2, 2018$12.79M
    Mar 31, 2018-$2.07-$0.87-$2.20 - $3.83-137.93%MissN/A17N/AMay 7, 2018$10.68M
    Dec 31, 2017-$1.89-$1.99-$2.26 - -$1.73+5.03%BeatN/A13N/AFeb 20, 2018$2.41M
    Sep 30, 2017-$1.87-$1.87-$1.98 - -$1.670.00%In lineN/A16N/ANov 2, 2017$198000
    Jun 30, 2017-$1.72-$1.71-$1.83 - -$1.59-0.58%MissN/A14N/AJul 27, 2017N/A
    Mar 31, 2017-$1.63-$1.71N/A+4.68%BeatN/AN/AN/AMay 4, 2017N/A
    Dec 31, 2016-$1.75-$1.73N/A-1.16%MissN/AN/AN/AFeb 16, 2017$5000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.84, after -$6.34 the year before. It was -$6.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.84N/A
    Dec 31, 2024-$6.34N/A
    Dec 31, 2023-$8.33N/A
    Dec 31, 2022-$9.85N/A
    Dec 31, 2021-$6.07N/A
    Dec 31, 2020-$5.71N/A
    Dec 31, 2019-$7.34N/A
    Dec 31, 2018-$7.41N/A
    Dec 31, 2017-$7.11N/A
    Dec 31, 2016-$6.20N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 19 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,37119
    2026Q2Jun 30, 20267,43423
    2026Q1Mar 31, 20268,62921
    2025Q4Dec 31, 20256,60519
    2025Q3Sep 30, 20252,4805
    2025Q2Jun 30, 20257,78723
    2025Q1Mar 31, 20258,87120
    2024Q4Dec 31, 20248,78315

    2026Q3 Earnings Call

    Opening remarks

    Joshua Higa Chief of Staff and Vice President of Investor Relations Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Howard Horn, Chief Financial Officer; Erik Harris, Chief Commercial Officer; and Eric Crombez, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.

    Emil Kakkis Chief Executive Officer and President Thanks, Josh, and good afternoon, everyone. The third quarter was a significant one for Ultragenyx in many ways. In August and September, the FDA approved GENGLYCOS for glycogen storage disease type Ia and FAYUVI for Sanfilippo syndrome type A. These approvals are the result of years of work by our teams and the original scientists, as well as the families, patients, and investigators who took part in the studies. We also saw the disappointing data from the GTX-102 Phase 3 that surprised us despite compelling Phase 2 data, which has now necessitated significant reductions across the company. These actions will bring our cost structure in line with our revenue. This enables us to be well positioned to continue commercializing our six products for patients with rare diseases and thoughtfully invest in our development programs, all while becoming a profitable company next year. While the clinical study miss on an important program that could create great value has challenged us, we should recognize all that the company has successfully accomplished in 12 years as a public company. We now have six product approvals for the first-ever treatment indications across multiple treatment modalities and are driving revenue growth globally of about 20% per year for multiple years, adding up to more than $1 billion in revenue and profitability. So while today we acknowledge the setback, when I started the company with $2 million in the secretary, I would have been surprised and inspired to know that we have become a highly respected, admired team of 1,000 professionals treating thousands of patients with rare and ultra-rare diseases worldwide. There is more work to do, and today we will outline the steps we are taking to move the company to its next stage as a profitable company, driving commercialization and development of first-ever treatments for rare diseases. To begin with, I'll focus on the launch of our two new gene therapy products. Both these products provide meaningful and transformative options for these rare disease patients and their families.

    Frequently Asked Questions About RARE

    When is Ultragenyx's next earnings date?

    Ultragenyx's next earnings report is expected for Feb 10, 2027.

    Did RARE beat earnings estimates last quarter?

    No. Ultragenyx reported EPS of -$1.16 for the quarter ended Sep 30, 2026, below the -$1.15 estimate by 0.87%.

    What EPS do analysts expect from RARE next quarter?

    The consensus EPS estimate for Ultragenyx for the quarter ending Dec 31, 2026 is -$0.51 from 22 analysts, with estimates from -$1.18 to $3.11.

    How often does RARE beat earnings estimates?

    Ultragenyx beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -3.86%.